Evaluation of clofazimine-bedaquiline combination as a candidate regimen for macrolide-resistant Mycobacterium avium complex infection
Antimicrobial Agents and Chemotherapy · 2026
DOI: 10.1128/aac.01511-25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2026. Verfasst von Jiyun Park und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Institute for Immunology and Immunological Disease, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei Un…. Hauptthemen laut MEDLINE: Mycobacterium avium Complex, Drug Resistance, Bacterial, Clofazimine, Antitubercular Agents. Die Arbeit nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Health Industry Development Institute, National Research Foundation of Korea.
Abstract (Originalsprache)
The Mycobacterium avium complex (MAC) is the primary cause of pulmonary disease (PD) among nontuberculous mycobacteria, presenting a significant treatment challenge on a global scale. A long-term (≥12 months) three-drug regimen, typically including a macrolide, such as clarithromycin (CLR) or azithromycin, along with rifampicin and ethambutol, is recommended. However, many patients fail to respond adequately to therapy, and some eventually develop macrolide resistance, making the disease even more difficult to treat. This highlights the urgent need for improved therapeutic strategies. Here, we investigated the efficacy of clofazimine (CFZ) and bedaquiline (BDQ), both repurposed from multidrug-resistant tuberculosis therapy, against macrolide-resistant MAC. In macrophage infection assays, both CFZ and BDQ showed significant intracellular inhibitory activity against macrolide-resistant clinical isolates, with CFZ generally exhibiting stronger effects. In a chronic murine model of MAC-caused progressive PD, substitution of CLR with CFZ and BDQ in the treatment regimen led to marked reductions in bacterial loads in both lung and spleen compared with the standard regimen, achieving up to 0.86 log₁₀ CFU reduction in lung and 2.17 log₁₀ CFU in spleen tissues. These findings demonstrate that CFZ and BDQ retain potent activity against macrolide-resistant MAC and highlight their potential as promising components of alternative treatment regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Institute for Immunology and Immunological Disease, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, Seoul, South Korea.
ORCID-Profile: Jiyun Park, Sangwon Choi, Lee-Han Kim, Ju Mi Lee, Sung Jae Shin
Förderung
- Korea Health Industry Development Institute
- National Research Foundation of Korea
Zitieren
APA
Park, J., Choi, S., Jeon, Y. R., Kim, L. H., Lee, J. M., & Shin, S. J. (2026). Evaluation of clofazimine-bedaquiline combination as a candidate regimen for macrolide-resistant Mycobacterium avium complex infection. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01511-25
Vancouver
Park J, Choi S, Jeon YR, Kim LH, Lee JM, Shin SJ. Evaluation of clofazimine-bedaquiline combination as a candidate regimen for macrolide-resistant Mycobacterium avium complex infection. Antimicrobial Agents and Chemotherapy. 2026. doi:10.1128/aac.01511-25
BibTeX
@article{Park2026,
author = {Park, Jiyun and Choi, Sangwon and Jeon, Yae Rin and Kim, Lee-Han and Lee, Ju Mi and Shin, Sung Jae},
title = {Evaluation of clofazimine-bedaquiline combination as a candidate regimen for macrolide-resistant Mycobacterium avium complex infection},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
doi = {10.1128/aac.01511-25}
}
EUVIMED